Literature DB >> 3015711

Intracolonic WR 2721 protection of the rat colon from acute radiation injury.

H G France, R L Jirtle, C M Mansbach.   

Abstract

The radioprotective thiophosphate compound WR 2721, when given intraperitoneally, has been shown to effectively protect normal murine tissues, but not tumors, from radiation injury. Intravenous administration in humans has produced limiting nausea and vomiting at protective doses. The accessibility of the colon, coupled with the frequency of acute radiation injury to the rectum during pelvic irradiation, stimulated us to determine if WR 2721 was radioprotective when administered intracolonically. Double-blind histologic evaluation of colons from irradiated rats treated with intracolonic WR 2721 demonstrated a radioprotective effect with a dose modifying factor of 1.8 when compared with controls. A contact time of 30-60 min was optimal as was a WR 2721 dose of at least 15 mg. No systemic absorption was found. These data demonstrate that WR 2721 exerts its radioprotective effect without the coincident development of secondary tissue hypoxia and provide rationale for a clinical trial in humans.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3015711     DOI: 10.1016/0016-5085(86)90634-7

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  9 in total

1.  [Prevention and therapy of acute radiation injuries of the skin and mucosa. I. Results of a German multicenter questionnaire].

Authors:  J S Zimmermann; R Wilhelm; P Niehoff; R Schneider; G Kovács; B Kimmig
Journal:  Strahlenther Onkol       Date:  1998-03       Impact factor: 3.621

Review 2.  Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.

Authors:  C R Culy; C M Spencer
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Randomized phase II exploratory study of prophylactic amifostine in cancer patients who receive radical radiotherapy to the pelvis.

Authors:  Konstantinos H Katsanos; Evangelos Briasoulis; Pericles Tsekeris; Anna Batistatou; Maria Bai; Christos Tolis; Antonio Capizzello; Ioannis Panelos; Vasileios Karavasilis; Dimitrios Christodoulou; Epameinondas V Tsianos
Journal:  J Exp Clin Cancer Res       Date:  2010-06-10

4.  Agents capable of eliminating reactive oxygen species. Catalase, WR-2721, or Cu(II)2(3,5-DIPS)4 decrease experimental colitis.

Authors:  A Keshavarzian; J Haydek; R Zabihi; M Doria; M D'Astice; J R Sorenson
Journal:  Dig Dis Sci       Date:  1992-12       Impact factor: 3.199

5.  Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in Quality of Life measured by EPIC score.

Authors:  Nicole L Simone; Cynthia Ménard; Benjamin P Soule; Paul S Albert; Peter Guion; Sharon Smith; Denise Godette; Nancy S Crouse; Linda C Sciuto; Theresa Cooley-Zgela; Kevin Camphausen; C Norman Coleman; Anurag K Singh
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-09-12       Impact factor: 7.038

6.  Effect of radiation and radioprotection on small intestinal function in canines.

Authors:  J L Herrera; R M Vigneulle; T Gage; T J MacVittie; J B Nold; A Dubois
Journal:  Dig Dis Sci       Date:  1995-01       Impact factor: 3.199

7.  Localized Delivery of Amifostine Enhances Salivary Gland Radioprotection.

Authors:  J J Varghese; I L Schmale; D Mickelsen; M E Hansen; S D Newlands; D S W Benoit; V A Korshunov; C E Ovitt
Journal:  J Dent Res       Date:  2018-04-10       Impact factor: 6.116

8.  Intestinal radioprotection by two new agents applied topically.

Authors:  J P Delaney; M Bonsack; P Hall
Journal:  Ann Surg       Date:  1992-10       Impact factor: 12.969

Review 9.  Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector.

Authors:  C M Spencer; K L Goa
Journal:  Drugs       Date:  1995-12       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.